Real world evidence of Lenvatinib + anti PD-1 as an advanced line for metastatic melanoma

Real world evidence of Lenvatinib + anti PD-1 as an advanced line for metastatic melanoma

IntroductionImmunotherapy has revolutionized the prognosis of patients with metastatic melanoma. To date, the most active regimen is the combination of ipilimumab + nivolumab (ipi-nivo) achieving a response rate of nearly 60% and a median survival (OS) of 6 years. However, approximately 40% of patie...

Full description

Bibliographic Details
Main Authors: Ronen Stoff, Nethanel Asher, Shachar Laks, Yael Steinberg, Jacob Schachter, Ronnie Shapira-Frommer, Shirly Grynberg, Guy Ben-Betzalel
Format: Article
Language:English
Published: Frontiers Media S.A. 2023-05-01
Series:Frontiers in Oncology
Subjects:
melanoma
Lenvatinib
immunotherapy
anti PD1
pembrolizumab
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2023.1180988/full

Internet

https://www.frontiersin.org/articles/10.3389/fonc.2023.1180988/full

Similar Items